Post-traumatic stress disorder (PTSD) can continue affecting a person long after a traumatic experience has ended. Intrusive memories, heightened alertness, emotional disconnection, sleep disruption, and persistent fear can interfere with relationships, work, and everyday responsibilities.
When PTSD occurs alongside depression that has not improved with previous treatment, finding an effective path forward may feel especially challenging.
At Pacific Mind Health, we provide individualized psychiatric care for people experiencing trauma and PTSD, depression, and other mental health conditions. Spravato® is not FDA-approved specifically for post-traumatic stress disorder. However, emerging research has examined whether esketamine may have a role in treating certain patients with PTSD and co-occurring treatment-resistant depression.
Considering Spravato for PTSD requires a comprehensive evaluation. Our clinicians review your symptoms, diagnoses, previous treatment, physical health, medications, and goals before recommending care.
Complete our new patient request form to discuss your symptoms and explore appropriate treatment options.
Spravato® is the brand name for esketamine, a prescription nasal spray that acts on the brain’s glutamate system. Its mechanism differs from that of conventional antidepressants, which typically target serotonin, norepinephrine, or dopamine.
The US Food and Drug Administration (FDA) has approved Spravato for adults with treatment-resistant depression, either as a standalone treatment or in combination with an oral antidepressant. It is also approved with an oral antidepressant for depressive symptoms in adults with major depressive disorder who are experiencing acute suicidal thoughts or behavior.
PTSD is not among these approved indications. Using Spravato with the intention of addressing PTSD symptoms would be considered off-label and would depend on a clinician’s judgment, the available evidence, and the patient’s broader psychiatric needs.
Our primary Spravato therapy page explains the medication, its approved uses, and the supervised treatment process in greater detail.
PTSD may develop after experiencing or witnessing a traumatic event. Symptoms can begin soon after the experience or emerge months or years later.
Common PTSD symptoms include:
Many people with PTSD also experience depression. When depressive symptoms continue despite multiple antidepressant trials, the person may meet the criteria for treatment-resistant depression and become eligible for a Spravato evaluation.
This distinction matters. A person does not automatically qualify for Spravato solely because they have PTSD.
Our psychiatric clinicians carefully evaluate which conditions are present and which symptoms each proposed treatment is intended to address.
Research involving esketamine and PTSD remains preliminary. Small observational studies have examined intranasal esketamine in patients with both treatment-resistant depression and PTSD. Some participants experienced improvements in depression and trauma-related symptoms, but these studies were limited by small sample sizes and the absence of large, controlled comparisons.
Other research has evaluated intravenous ketamine for PTSD. Ketamine and esketamine are related, but they are different medications with different formulations, administration methods, dosing protocols, and regulatory statuses. Results involving intravenous ketamine cannot automatically be applied to Spravato nasal spray.
Current research has not conclusively established:
Because the evidence is still developing, we do not position Spravato as a replacement for proven trauma care. Our role is to explain the evidence honestly and recommend treatment based on your individual clinical needs.
A Spravato evaluation may be appropriate when an adult has PTSD alongside an FDA-approved depressive indication, such as treatment-resistant depression. Eligibility depends on more than the severity of trauma symptoms.
Our evaluation may consider:
Spravato can cause dissociation and changes in perception. For some people with PTSD, treatment may also bring up distressing memories or flashback-like experiences. This possibility makes careful screening, preparation, monitoring, and open communication especially important.
Contacting us at Pacific Mind Health begins an evaluation rather than confirming that Spravato will be recommended. Depending on what we learn, your plan may instead include medication management, psychotherapy, TMS, or another service.
Spravato is not taken independently at home. Patients self-administer the nasal spray under professional observation at a certified healthcare setting.
Before each appointment, we review your symptoms and check your blood pressure. You then remain onsite for at least two hours so our team can monitor your response and determine when you are ready to leave.
Temporary effects may include:
You must arrange for someone to drive you home after each session. You should not drive, operate machinery, or perform tasks requiring full alertness until the following day after a restful night of sleep.
Our main Long Beach office offers a structured clinical environment for treatment. Before beginning care, we explain the process, monitoring requirements, transportation needs, and potential side effects so you can make an informed decision.
When Spravato is considered for someone with PTSD and treatment-resistant depression, it should be part of a broader treatment plan. Reducing depression may improve energy, motivation, or engagement, but it does not automatically process traumatic memories or change trauma-related avoidance patterns.
Psychotherapy can help individuals understand their reactions, build emotional regulation skills, and gradually address the effects of trauma. Cognitive behavioral therapy may also help patients recognize unhelpful beliefs, develop coping strategies, and respond differently to distressing thoughts.
Treatment may focus on:
Our broader mental health treatment services allow us to coordinate care based on your symptoms rather than relying on one intervention alone.
Spravato may not be appropriate for every person. Our clinicians can help you compare other evidence-based or clinically appropriate options.
For people with persistent depression, TMS therapy offers a noninvasive approach using targeted magnetic stimulation. We also provide Accelerated TMS for qualifying patients seeking a condensed treatment schedule.
Psychiatric medication, trauma-focused psychotherapy, lifestyle support, or a coordinated combination of services may be recommended instead. Our goal is to identify an approach that reflects your diagnosis, history, preferences, and safety needs.
Living with PTSD and persistent depression can make it difficult to feel hopeful about treatment. An incomplete response to previous care, however, does not mean you have exhausted every appropriate option.
At Pacific Mind Health, we provide thoughtful evaluations, clear clinical guidance, and compassionate support. We will explain what Spravato is approved to treat, what the early PTSD research suggests, where uncertainty remains, and which alternatives may better meet your needs.
Complete our new patient request form to connect with our team. We will review your trauma symptoms, depression history, previous treatments, and current goals before helping you determine an appropriate next step.
